Shots:

• The company has launched Guardant Reveal liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw to monitor CRC patients with 7-day turnaround time- residual disease after surgery and recurrence mos. earlier than current SoC methods like CEA tests or imaging
• The test can deliver industry leading sensitivity of 91% for detecting ctDNA by simultaneously interrogating both genomic alterations and methylation. Additionally- it reports genomic alterations down to allele frequencies of 0.01%- and effectively filters out biological noise sources
• The Guardant Reveal test is company’s 1^st commercially available liquid biopsy test for clinical use in the management of early-stage cancer which will focus first on early-stage CRC and later on additional cancer types

 ­ Ref: Guardant Health | Image: Guardant Health